SAVARA ANNOUNCES CLOSING OF MERGER WITH MAST THERAPEUTICS Commences Trading on Nasdaq Capital Market on

SAVARA ANNOUNCES CLOSING OF MERGER WITH MAST THERAPEUTICS

Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol SVRA

Conference Call Scheduled for Tuesday May 2nd, 2017 at 4:30 p.m. ET / 3:30 p.m. CT

AUSTIN, TX April 27, 2017 Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical

company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of its previously announced merger with Mast Therapeutics, Inc. (NYSE

MKT: MSTX), under which the stockholders of Savara have become the majority owners of Mast, and the operations of Mast and Savara have combined. The post-merger company, named Savara Inc., is based in Austin, TX and features three inhaled product

candidates, each in advanced stages of clinical development. The company will be led solely by Savara s current management team. Two independent members of the Mast board remain on the post-merger board together with all five members of the

Savara board. Savara s common stock will commence trading on April 28th, 2017 on the Nasdaq Capital Market under the trading symbol SVRA .

Savara s transition to the public market marks a significant milestone for us, and serves as testament to the determination of our team as well as

the support of our investors to date, stated Rob Neville, Chairman and CEO of Savara. Savara s team is passionate about helping those who suffer from rare and debilitating lung diseases and will dynamically pursue opportunities to

develop impactful products to treat such conditions. We believe Savara presents an attractive business opportunity with our pipeline of unique products with considerable market potential, as well as significant value-driving clinical

Savara began the development of AeroVanc in 2010 and is now in preparation for a pivotal Phase 3 study. In July 2016, Savara acquired

Serendex Pharmaceuticals adding Molgradex to its pipeline. Molgradex is currently in Phase 2/3 development. With the closing of the Mast merger, Savara adds the Aironite program to its pipeline (also known as AIR001). Savara intends to continue its

growth strategy focused on indication expansion, strategic development partnerships and product acquisitions.

In connection with the closing of the

merger, Mast effected a 1 for 70 reverse split of its common stock. Post-merger and post-reverse split, Savara has approximately 15 million shares of common stock issued and outstanding with prior Savara stockholders collectively owning

approximately 77% of the combined company, and prior Mast stockholders collectively owning approximately 23% of the combined company. Prior to the merger closing, Savara stockholders exercised certain previously issued warrants to purchase Savara

shares and invested additional capital into the company, resulting in aggregate net proceeds of approximately $4 million.

Savara s pipeline now

Select Development Milestones

Conference Call and Webcast

conference call on Tuesday May 2nd, 2017, at 4:30 p.m. Eastern Time / 3:30 p.m. Central Time to provide an overview and business update. Interested parties may access the conference call by

dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from outside the U.S. and should request the

Savara Inc. Call. A live webcast of the conference call will be available online from the Investors section of Savara s website at http://www.savarapharma.com/investors/events/. Replays of the webcast will be available on Savara s

website for 30 days and a telephone replay will be available through May 9th, 2017 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada, and (412) 317-0088 from elsewhere outside the U.S. and entering replay access code 10104600.

Savara Inc. is a clinical-stage specialty

pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara s pipeline comprises AeroVanc, a Phase 3 ready inhaled vancomycin,

Molgradex, a Phase 2/3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF and Aironite, an inhaled nebulized sodium nitrite solution to treat HFpEF. Savara s strategy involves

expanding its pipeline of best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a

leading company in its field. Savara s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, creating and acquiring new product candidates, and effectively advancing them to

approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as expect, intend, plan,

anticipate, believe, and will, among others. Such statements include, but are not limited to, statements regarding dynamically pursuing opportunities to develop impactful products, Savara presenting an attractive

business opportunity with a pipeline of unique products with considerable market potential, as well as significant value-driving clinical milestones, Savara s intent to continue its growth strategy focused on indication expansion, strategic

development partnerships and product acquisitions, Savara s pipeline and select developmental milestones. Savara may not actually achieve any of the matters referred to in such forward looking

statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from

those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the

timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the ability to project

future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara s operations and to conduct or continue planned clinical development programs, the timing

and ability of Savara to raise additional equity capital to fund continued operations; the ability to successfully develop Savara s product candidates, and the risks associated with the process of developing, obtaining regulatory approval for

and commercializing drug candidates that are safe and effective for use as human therapeutics. Risks and uncertainties facing Savara are described more fully in Savara s filings with the Securities and Exchange Commission including the most

recent Form 8-K filed on April 27, 2017, other filings on Form 8-K, the Annual Report on Form 10-K for the fiscal year ended

December 31, 2016 and the Registration Statement on Form S-4 related to the Mast/Savara merger. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date

on which they were made. Savara undertakes any obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Ioana C. Hone (ir@savarapharma.com)